Page 296 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 22 Natural Killer Cell Immunity 246.e1

REFERENCES 27. Trotta R, Parihar R, Yu J, et al: Differential expression of SHIP1 in
dim
CD56 bright and CD56 natural killer cells provides a molecular basis for
1. Robertson MJ, Ritz J: Biology and clinical relevance of human natural distinct functional responses to monokine stimulation. Blood 105:3011,
killer cells. Blood 76:2421, 1990. 2005.
2. Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural 28. Becknell B, Hughes TL, Freud AG, et al: The Hlx homeobox transcrip-
killer cell subsets. Trends Immunol 22:633, 2001. tion factor negatively regulates interferon-γ production in monokine-
3. Herberman RB, Holden HT: Natural cell-mediated immunity. Adv activated natural killer cells. Blood 109:2481, 2007.
Cancer Res 27:305, 1978. 29. Trotta R, Dal Col J, Allard J, 2nd, et al: In vitro and in vivo evidence
4. Kitchens WH, Uehara S, Chase CM, et al: The changing role of that the PP2A inhibitor SET regulates IFN-γ production in monokine-
natural killer cells in solid organ rejection and tolerance. Transplantation stimulated natural killer cells. Blood 108:928, 2006.
81:811, 2006. 30. Yu J, Freud AG, Caligiuri MA: Location and cellular stages of natural
5. Biron CA, Byron KS, Sullivan JL: Severe herpesvirus infection in an killer cell development. Trends Immunol 34:573, 2013.
adolescent without natural killer cells. N Engl J Med 320:1731, 1989. 31. Spits H, Artis D, Colonna M, et al: Innate lymphoid cells—a proposal
6. Kim S, IIzuka K, Aguila HL, et al: In vivo natural killer cell activities for uniform nomenclature. Nat Rev Immunol 13:145, 2013.
revealed by natural killer cell deficient mice. Proc Natl Acad Sci USA 32. Vosshenrich CA, Ranson T, Samson SI, et al: Roles for common cytokine
97:2731, 2000. receptor γ-chain-dependent cytokines in the generation, differentiation
7. Smyth MJ, Thia KY, Street SE, et al: Differential tumor cell surveillance and maturation of human NK cell precursors and peripheral NK cells
by natural killer (NK) and NKT cells. J Exp Med 191:661, 2000. in vivo. J Immunol 174:213, 2005.
8. Lanier LL, Le AM, Civin CI, et al: The relationship of CD16 (Leu-11) 33. Kawamura T, Koka R, Ma A, et al: Differential roles for IL-15Ra-chain
and Leu-19 (NKH-1) antigen expression on human peripheral blood in NK cell development and Ly-49 induction. J Immunol 171:5085,
NK cells and cytotoxic T lymphocytes. J Immunol 136:4480, 1986. 2003.
9. Lanier LL, Testi R, Bindl J, et al: Identify of Leu-19 (CD56) leukocyte 34. Colucci F, Caligiuri MA, Di Santo JP: What does it take to make a
differentiation and neural cell adhesion molecule. J Exp Med 169:2233, natural killer? Nat Rev Immunol 3:413, 2003.
1989. 35. Freud AH, Yokohama A, Becknell B, et al: Evidence for discrete stages
10. Cooper MA, Fehniger TA, Turner SC: Human natural killer cells: A of human natural killer cell differentiation in vivo. J Exp Med 203:1033,
unique innate immunoregulatory role for the CD56 bright subset. Blood 2006.
97:3146, 2001. 36. Freud AG, Caligiuri MA: Human natural killer cell development.
11. Voss SD, Daley J, Ritz J, et al: Participation of the CD94 receptor Immunol Rev 214:56, 2006.
complex in costimulation of human natural killer cells. J Immunol 37. Yu J, Mao HC, Wei M, et al: CD94 surface density identifies a
dim
160:1618, 1998. functional intermediary between the CD56 bright and CD56 human
12. Becknell B, Caligiuri MA: Interleukin-2, interleukin-15, and their roles NK-cell subsets. Blood 15:274, 2010.
in human natural killer cells. Adv Immunol 86:209, 2005. 38. Lopez-Verges S, Milush J, Pandey S, et al: CD57 defines a functionally
dim
+
13. Makrigiannis AP, Anderson SK: Regulation of natural killer cell func- distinct population of mature NK cells in the human CD56 CD16
tion. Cancer Biol Ther 2:610, 2003. NK-cell subset. Blood 116:3865, 2010.
14. Djeu JY, Jiang K, Wei S: A view to a kill: Signals triggering cytotoxicity. 39. Karre K, Ljunggren HG, Piontek G, et al: Selective rejection of H-2
Clin Cancer Res 8:636, 2002. deficient lymphoma variants suggests alternative immune defense
15. Trinchieri G: Biology of natural killer cells. Adv Immunol 47:187, 1989. strategy. Nature 319:675, 1986.
16. Sun PD: Structure and function of natural killer cell receptors. Immunol 40. Biassoni R, Cantoni C, Pende D, et al: Human natural killer cell
Res 27:539, 2003. receptors and co-receptors. Immunol Rev 181:203, 2001.
17. Nagler A, Lanier LL, Cwirla S, et al: Comparative studies of human 41. Dohring C, Scheidegger D, Samaridis J, et al: A human killer inhibitor
FcRIII-positive and negative natural killer cells. J Immunol 143:3183, receptor specific for HLA-A1, 2. J Immunol 156:3098, 1996.
1989. 42. Litwin V, Gumperz J, Parham P, et al: NKB1: A natural killer cell
18. Farag SS, Fehniger TA, Ruggeri L, et al: Natural killer cell receptors: receptor involved in the recognition of polymorphic HLA-B molecules.
New biology and insights into the graft-versus-leukemia effect. Blood J Exp Med 180:537, 1994.
100:1935, 2002. 43. Wagtmann N, Rajagopalan S, Winter CC, et al: Killer cell inhibitory
19. Campbell JJ, Hedrick J, Zlotnik A, et al: Chemokines and the arrest of receptors specific for HLA-C and HLA-B identified by direct binding
lymphocytes rolling under flow conditions. Science 279:381, 1998. and functional transfer. Immunity 3:801, 1995.
20. Smyth RL, Mobbs K, O’Hea U, et al: The association between disease 44. Colonna M, Samaridis J: Cloning of immunoglobulin-superfamily
severity, cytokines and virus genotype in infants with respiratory syncy- members associated with HLA-C and HLA-B recognition by human
tial virus (RSV) bronchiolitis [abstract P18]. Arch Dis Child 82(Suppl natural killer cells. Science 268:405, 1995.
1):A4, 2000. 45. Lanier LL: NK cell recognition. Annu Rev Immunol 23:225, 2005.
21. Chen JJ, Yao PL, Yuan A, et al: Up-regulation of tumor interleukin-8 46. Vales-Gomez M, Reyburn HT, Mandelboim M, et al: Kinetics of
expression by infiltrating macrophages: Its correlation with tumor interaction of HLA-C ligands with natural killer cell inhibitor receptor
angiogenesis and patient survival in non-small cell lung cancer. Clin genes. Immunity 7:753, 1997.
Cancer Res 9:729, 2003. 47. Loke YW, King A: Immunology of human placental implantation:
22. Sutton A, Friand V, Brule-Donneger S, et al: Stromal cell-derived Clinical implications of our current understanding. Mol Med Today
factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepa- 3:153, 1997.
toma cell growth, migration, and invasion. Mol Cancer Res 5:21, 2007. 48. Rajagopolan S, Fu J, Long EO: Induction of IFN-γ production but
23. Aggarwal R, Ghobrial IM, Roodman GD: Chemokines in multiple not cytotoxicity by the killer Ig-like receptor KIR2DL4 (CD158d) in
myeloma. Exp Hematol 34:1289, 2006. resting NK cells. J Immunol 167:1877, 2001.
24. Kalinkovich A, Tavor S, Avigdor A, et al: Functional CXCR4-expressing 49. Ashkar AA, DiSanto JP, Croy BA: Interferon γ contributes to initiation
microparticles and SDF-1 correlate with circulating acute myelogenous of uterine vascular modification, decidual integrity, and uterine natural
leukemia cells. Cancer Res 66:11013, 2006. killer cell maturation during normal murine pregnancy. J Exp Med
25. Fehniger TA, Cooper MA, Nuovo GJ, et al: CD56 bright natural killer 192:259, 2000.
cells are present in human lymph nodes and are activated by T cell 50. Lanier LL: NK cell receptors. Annu Rev Immunol 16:359, 1998.
derived IL-2: A potential new link between adaptive and innate immu- 51. Borrego F, Masilamani M, Marusina AT: The CD94/NKG2 family of
nity. Blood 101:3052, 2003. receptors: From molecules and cells to clinical relevance. Immunol Res
+
26. Freud AH, Becknell B, Roychowdhury S, et al: A human CD34 subset 35:263, 2006.
resides in lymph nodes and differentiates into CD56 bright NK cells. 52. Moser JM, Gibbs J, Jensen PE, et al: CD94-NKG2A receptors regulate
+
Immunity 22:295, 2005. antiviral CD8 T cell responses. Nat Immunol 3:189, 2002.